Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-09-06

Clinical Trial Update: Phase l/II Study of Ruxolitinib for Acute Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II study of ruxolitinib in acute leukemia was terminated, and trial results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ruxolitinib (ruxolitinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-09-06